What are your top takeaways in Medical Oncology from SABCS 2024?   

PATINA Trial: The PATINA trial evaluated the addition of palbociclib, a CDK4/6 inhibitor, to standard HER2-targeted therapy and endocrine therapy in patients with ER+/HER2+ metastatic breast cancer. The study involved 518 patients who had undergone six cycles of initial treatment with taxane,...

I was very impressed by the increased efficacy seen by adding palbociclib to endocrine therapy + H/P in the PATINA trial I was excited to see the combination data of an oral SERD and a CDK4,6 inhibitor in the EMBER trial  I thought the post hoc analysis of TAILORx showing the additional ben...

EMBER-3 – a new SERD that works in ESR1mt patients AND can be combined with CDK4/6i (and work in ESR1mt or wt), including after CDK4/6i. PATINA – adding CDK4/6i to anti-HER2 and ET in MBC COMET – potential for watchful waiting in low-risk DCIS

I would give the following studies the top 3 in terms of impact: GS2-12:The PATINA study, that tested the use of palbociclib in patients who were on maintenance first-line therapy after induction therapy for metastatic HER2 and hormone receptor-positive breast cancer with taxane or vinorelbine plus...

The AFT-38 PATINA Trial for triple positive metastatic breast cancer. This was a phase III study of adding palbociclib to the first line treatment maintenance regimen. In this study, all triple positive patients (n=518) completed a standard six cycles of THP therapy and then there was a randomizat...

1. AFT-38 PATINA, Phase III study of Maintenance therapy with palbociclib plus endocrine therapy and trastuzumab+/-pertuzumab vs. endocrine therapy+ Trastuzumab+/-pertuzumab after 6- 8 cycles of induction chemotherapy for HR+ Her2 negative metastatic breast cancer:Triple-positive metastatic breast c...

ZEST trial showing the difficulty in using ctDNA to escalate therapy in curative setting. Need to work on sensitivity and testing schedules to optimize how we use these tests to improve cure rates while personalizing therapy. PATINA is solid phase 3 data to enable us to add palbociclib in ER+HER2...

1. Imlunestrant (EMBER-3 Trial)Imlunestrant, a novel oral estrogen receptor (ER) degrader, showed marked improvements in progression-free survival among patients with ER-positive/HER2-negative advanced breast cancer, especially those harboring ESR1 mutations. Phase 3 findings from the EMBER-3 trial ...

AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast Cancer: The stu...

GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2-Breast CancerIn patients with HR+/HER2-negative, node-negative breast cancer, a post hoc analysis of over 2,500 patients from the TAILORx trial showed benefit to the addition of anthracyclines to a taxane-based chemothera...

Some of the important presentations were concerning local-regional management. 1. LB1-01: omission or reduction in the extent of surgery led to higher local recurrence, lower DDFS at 15 years, and higher BC-related mortality (from Oxford overview). However, the difference was not seen in the first ...

The addition of palbociclib to maintenance HER2-directed and endocrine therapy significantly improves PFS in patients with hormone receptor-positive, HER2-positive metastatic breast cancer

The PATINA study was a randomized phase 3 study for patients with metastatic triple positive breast cancer. Participants received induction chemotherapy with HP as part of first line treatment of triple positive breast cancer and were randomized to palbociclib with anti-HER2 therapy and endocrine th...